Ozempic and Mounjaro, which are diabetes drugs, have gained immense popularity both domestically and globally for their remarkable weight-loss effects.
Novo Nordisk, the exclusive manufacturer of Ozempic and the patent holder for semaglutide, has declared in a statement it does not supply the ingredient to pharmacies. Adverse side effects have led to warnings from authorities about the use of these white-label alternatives. Pharmacies found flouting this regulation post-October risk facing severe civil and criminal penalties under the Therapeutic Goods Act.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: abcnews - 🏆 5. / 83 Read more »